Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Eli Lilly’s popular obesity injection Zepbound trounces Novo Nordisk’s Wegovy when it comes to shedding weight, according to new research published Monday, intensifying competition between the two pharma giants as theyObese and overweight adults taking tirzepatide lost more weight and lost it faster than adults taking semaglutide according to new peer reviewed
The findings come from an analysis of the electronic health records of more than 18,000 U.S. adults who were receiving either drug between May 2022 and September 2023 and had their weight loss monitored over the course of a year, with subjects “matched” to reduce the chance of variables like other health conditions influencing the outcome.
When measured at three-, six- and 12-month milestones, the adults taking tirzepatide lost 2.4% more weight at three months, 4.3% more at six months and 6.9% more at 12 months, the researchers said, adding that while clinical outcomes varied, both groups experienced similar side effects at similar rates.
Ozempic Semaglutide Tirzepatide Zepbound Mounjaro Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Added Health Benefits Of Wegovy, Zepbound Could Attract More Men, Doctors SayEvidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart disease risk, treat sleep apnea and address other health issues may help...
Read more »
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Lilly, maker of Zepbound, files lawsuits over compounded tirzepatideThere is an all-hands-on-deck effort by drugmakers to produce more weight-loss medications, but a shortage could continue into 2025. NBC’s Christine Romans reports for TODAY on how companies are trying to keeping up with demand.
Read more »
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Eli Lilly warns about dangers of fake and counterfeit Mounjaro, ZepboundEli Lilly also filed lawsuits against compounding pharmacies and medical spas.
Read more »
Obesity drug used in Mounjaro and Zepbound may help treat dangerous sleep apneaA new study finds the popular obesity drug Zepbound may help treat sleep apnea, a dangerous disorder in which people struggle to breathe during sleep.
Read more »